Parasympathetic autonomic dysfunction is more often evidenced than sympathetic autonomic dysfunction in fluctuating and polymorphic symptoms of "long-COVID" patients.

Several disabling symptoms potentially related to dysautonomia have been reported in "long-COVID" patients. Unfortunately, these symptoms are often nonspecific, and autonomic nervous system explorations are rarely performed in these patients. This study aimed to evaluate prospectively a cohort of long-COVID patients presenting severe disabling and non-relapsing symptoms of potential dysautonomia and to identify sensitive tests.

Narcolepsy secondary to anti-Ma2 encephalitis: two case reports.

Unlabelled: Recent studies suggest that sleep disorders are present in two-thirds of patients with autoimmune encephalitis. In anti-Ma2 encephalitis, hypersomnia appears to be frequent. However, only few cases of type 1 narcolepsy have been reported to date with anti-Ma2 encephalitis.

Effect of high polyol concentrations on the neutral red absorption assay and tetrazolium-MTT test of rat hepatocytes in primary culture.

The effects of three polyols, mannitol, sorbitol and xylitol, on primary cultures of rat hepatocytes were studied with the aid of two cytotoxicity markers, the MTT test and the neutral red assay. A dose-related increase in the uptake of neutral red (up to approximately 60%) was observed in comparison with untreated cells, whereas the MTT test was unaffected by concentrations of polyols up to 330 mM (620 mOsmol/litre). The increase in neutral red uptake does not indicate cellular toxicity as it was reversible and was shown to be due to an increase in the size of lysosomes.

Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.

In vitro and in vivo data have indicated that tumor cells actively internalize the low-density lipoprotein (LDL) from the circulation. A family of 2-(aminomethyl) acrylophenones (AMA) possesses an in vitro antileukemic activity but is devoid of any in vivo antineoplastic activity, because the compounds are actively captured by proteins in solution in the blood. In order to achieve a selective delivery of these drugs via the LDL pathway, we have incorporated an AMA drug, 2-morpholinomethyl-2',3',4'- trimethoxy acrylophenone hydrochloride (ILE) into LDL particles.